Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Organon & Co. (NYSE:OGN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.
Analyst Ratings
This is a breakdown of current ratings and price targets for Unicycive Therapeutics and Organon & Co., as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Unicycive Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| Organon & Co. | 2 | 5 | 0 | 0 | 1.71 |
Unicycive Therapeutics currently has a consensus target price of $18.25, indicating a potential upside of 398.63%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 17.93%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Unicycive Therapeutics is more favorable than Organon & Co..
Profitability
This table compares Unicycive Therapeutics and Organon & Co.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Unicycive Therapeutics | N/A | -91.50% | -61.47% |
| Organon & Co. | 3.49% | 82.06% | 6.03% |
Risk & Volatility
Unicycive Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
Valuation & Earnings
This table compares Unicycive Therapeutics and Organon & Co.”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Unicycive Therapeutics | $680,000.00 | 149.90 | -$26.56 million | ($1.75) | -2.09 |
| Organon & Co. | $6.22 billion | 0.59 | $187.00 million | $0.76 | 18.28 |
Organon & Co. has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Organon & Co. beats Unicycive Therapeutics on 8 of the 14 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis. Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.
About Organon & Co.
Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
